What this pack is
Lanoxin is the brand name in this record; digoxin is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
LanoxinGeneric namedigoxin
How this medicine works
The current tablet label describes digoxin inhibition of Na+/K+-ATPase and resulting effects on intracellular ions and myocardial contraction. This helps explain why units, kidney function, interactions, rate/rhythm and monitoring need professional review; it does not predict an individual's effect or amount.
Read source: United States ↗Current regulatory record · reviewed 2026-09-05More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Lanoxin
- Generic name
- digoxin
- Dosage-form class
- Oral tablets: 62.5 mcg, 125 mcg and 250 mcg (as listed in the current U.S. tablet label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
1 mg = 1000 mcg. This relationship prevents a thousand-fold unit error; it is not a personal dose converter.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Prescribing information revised Dec 2024; DailyMed SPL v12 published 9 Jan 2025
62.5 mcg per tablet; 100-tablet bottle
- Product code
- NDC 59212-240-55
- Form and route
- digoxin oral tablet · oral
- Container
- 100-tablet bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- digoxin
- 62.5 mcglabelled amount per tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- peach/orange · 5 mm round tablet · imprint LANOXIN / U3AUnscored in this labelled presentation
United States label · Prescribing information revised Dec 2024; DailyMed SPL v12 published 9 Jan 2025
125 mcg per tablet; 100-tablet bottle
- Product code
- NDC 59212-242-55
- Form and route
- digoxin oral tablet · oral
- Container
- 100-tablet bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- digoxin
- 125 mcglabelled amount per tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- yellow · 6 mm round tablet · imprint LANOXIN / Y3BScored in this labelled presentation
United States label · Prescribing information revised Dec 2024; DailyMed SPL v12 published 9 Jan 2025
125 mcg per tablet; institutional unit-dose pack (10 blisters × 10 tablets)
- Product code
- NDC 59212-242-56
- Form and route
- digoxin oral tablet · oral
- Container
- institutional unit-dose pack (10 blisters × 10 tablets)
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- digoxin
- 125 mcglabelled amount per tablet
- Package
- 100 tablets per unit-dose carton
- Labelled appearance
- yellow · 6 mm round tablet · imprint LANOXIN / Y3BScored in this labelled presentation
United States label · Prescribing information revised Dec 2024; DailyMed SPL v12 published 9 Jan 2025
250 mcg per tablet; 100-tablet bottle
- Product code
- NDC 59212-249-55
- Form and route
- digoxin oral tablet · oral
- Container
- 100-tablet bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- digoxin
- 250 mcglabelled amount per tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- white · 7 mm round tablet · imprint LANOXIN / X3AScored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
LANOXIN label reading: mcg and mg differ by a thousand-fold, and dosage form must remain separate
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module only helps check the tablet brand, mcg per tablet, NDC, score and pack; it does not generate tablet counts, splitting, serum targets, missed-use, conversion or stopping.
- 1 mg = 1000 mcg. The 62.5/125/250 mcg labels equal 0.0625/0.125/0.25 mg respectively; 125 mg is not 125 mcg but a thousand-fold larger. This relationship prevents unit misreading; it is not a personal dose converter.
- The 125 mcg tablet appears in both a 100-tablet bottle and an institutional unit-dose pack, so NDC and pack still matter. A different pack does not automatically change the amount per tablet or determine an individual's tablet count.
- The 62.5 mcg tablet is unscored; the 125 mcg and 250 mcg tablets are labelled as scored. A score is an appearance clue for an exact presentation, not permission for a webpage to decide whether or how someone splits a tablet.
- LANOXIN injection has a different NDA, SPL, route and concentration expression; generic digoxin oral solution is also not this tablet record. A shared brand or generic name does not support self-conversion by mcg, mL or route.
- With nausea/vomiting, persistent diarrhoea, marked weakness or confusion, visual disturbance, palpitations/fainting or suspected misuse, promptly contact local clinicians, pharmacists, poison-control or emergency support; do not self-make-up, stop or change an amount from this page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-05
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. LANOXIN digoxin-tablet label (Advanz Pharma; revised Dec 2024) ↗Current regulatory record · reviewed 2026-09-05
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Lanoxin (digoxin). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Lanoxin is the brand in this record and digoxin is the active-ingredient name. Check both with the dosage form (Oral tablets: 62.5 mcg, 125 mcg and 250 mcg (as listed in the current U.S. tablet label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When CORDARONE / amiodarone is on the same list: digoxin concentration and rate/conduction need professional review
The current U.S. LANOXIN tablet label says toxic digoxin concentrations are only slightly higher than therapeutic concentrations, and that age, body weight, renal function and concomitant medicines matter when a regimen is selected; its interaction table also lists increased serum digoxin concentration with amiodarone. A current U.S. generic amiodarone label separately lists digoxin as a negative chronotrope that can add to bradycardia, sinus arrest and AV block. This card only calls for prompt review of both actual packs, the complete medicine list, recent kidney-function/electrolyte information, heart-rate or ECG records and any existing digoxin-monitoring results by the prescribing team or pharmacist. It does not decide co-use or provide a concentration target, reduction percentage, timing interval, stop or switch plan, and does not advise self-separation, tablet splitting, catch-up use or adjustment of either medicine. The CORDARONE page is a historical brand archive; a current generic label does not establish current brand supply.
Open the CORDARONE / amiodarone hydrochloride record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-09-05HOW IT WORKS · NOT A TREATMENT PLAN
How digoxin works: the label describes Na+/K+-ATPase inhibition and cardiac effects
- Mechanism cannot determine from symptoms or a watch reading whether someone needs digoxin or whether one serum result warrants a change. Diagnosis, sampling time and interpretation need professionals with the exact product and clinical context.
- Effects on rate/conduction do not make LANOXIN self-combinable, alternatable, substitutable or milligram-convertible with another rhythm, heart-failure or blood-pressure product. The complete medicine list, kidney function and electrolyte context all need review.
- Mechanism cannot manage suspected toxicity, marked palpitations, fainting, confusion or severe gastrointestinal/visual symptoms; prioritise local urgent medical support for an acute serious concern.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. LANOXIN digoxin-tablet label (Advanz Pharma; revised Dec 2024) ↗Current regulatory record · reviewed 2026-09-05
SOURCE-TRACEABLE ARCHIVE
Lanoxindigoxin
This page includes an exact current U.S. public-label package panel for Lanoxin, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the label
The current LANOXIN tablet label lists Initial U.S. Approval: 1954; that year does not establish status in another market.
DailyMed: current LANOXIN tablet public label ↗Current prescribing-information update/revision
DailyMed lists Drug Label Information Updated as 5 Dec 2024 and the prescribing information as Revised 12/2024.
DailyMed: current LANOXIN tablet public label ↗DailyMed SPL v12 published
DailyMed marks v12 as current and lists Published 9 Jan 2025; this remains separate from the prescribing-information revision month.
DailyMed: current LANOXIN tablet public label ↗
MARKET SCOPE
Market-record boundary
United States tablets
Current NDA 020405 public label linkedThe four presentations correspond only to active packs in the current Advanz tablet label.
LANOXIN injection, generic digoxin oral solution and other markets
Explicitly separate or not establishedA different NDA, SPL, form, route or brand status is not merged into this tablet dossier.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Is 125 mcg the same as 125 mg?
No. 1 mg = 1000 mcg, so 125 mcg = 0.125 mg. This equivalence only prevents unit misreading and does not determine anyone's tablet count or amount.
If digoxin and amiodarone are both on the medicine list, can the previous routine simply continue?
A webpage cannot confirm that. Current official labels flag both increased digoxin concentration and rate/conduction concerns with this combination. Promptly have the prescribing team or pharmacist review both actual packs, the complete medicine list, kidney function, electrolytes, heart-rate/ECG information and existing monitoring results. Do not self-stop, separate, split, catch up or adjust either medicine.
Why should an older adult on the same digoxin routine still review kidney function and newly added medicines?
The current LANOXIN label identifies advanced age, low body weight, impaired renal function and electrolyte abnormalities as toxicity risk factors. Digoxin is mainly excreted by the kidneys, and co-medications may alter its concentration or rate/conduction effects. Any change requires professional interpretation of the exact product, tests and monitoring; this page provides no reduction or stopping decision.
What should someone do if nausea, visual changes, marked weakness, palpitations or fainting occurs while taking digoxin?
These can be warning signs requiring prompt assessment, but a webpage cannot determine the cause. Contact the responsible team immediately; severe symptoms, fainting, marked altered awareness, serious chest discomfort or another acute danger sign requires local emergency care. Do not wait for a web answer or self-catch-up, stop or switch.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.